ReviewFrontiers in immunology2020
The Immune Response and Immunopathology of COVID-19.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 217 citations in OpenAlex.
- Trial
- The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.European journal of pharmacology · 2022Trial
- Dynamic immune response and its influencing factors in COVID-19 patients with non-alcoholic fatty liver disease: A cohort study.World journal of hepatology · 2026Article
- Co-infection of SARS-CoV-2 and DENV case report in Jazan Region Southwest Saudi Arabia.BMC infectious diseases · 2026Article
- mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications.Frontiers in microbiology · 2026Review
- Successful Treatment of Multiple Myeloma Complicated With SARS-CoV-2 Infection: A Case Report.Case reports in medicine · 2026Article
- IL-2 and IL-7 Contribution to Immune Response: Effects of Vaccination Against COVID-19 in Adults.Viruses · 2025Article
- Clinical risk factors of long-term post-traumatic stress symptoms, anxiety, and depression in COVID-19 survivors.European archives of psychiatry and clinical neuroscience · 2025Article
- Long COVID and Type I IFN Signature in Working-Age Adults: A Cross-Sectional Study.International journal of molecular sciences · 2025Article
- Association Between COVID-19 Infection and Thyroid Cancer Development: A Retrospective Cohort Study Using the TriNetX Database.Biomedicines · 2025Article
- Age influences blood cell-based immune deregulation antibody response and unfavorable clinical outcomes in COVID-19 patients.Scientific reports · 2025Article
- COVID-19 Vaccine Uptake Inequality Among Children: A Multidimensional Demographic Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Humoral response against COVID-19 in the population of western region of Poland.Frontiers in public health · 2025Article
- Concomitant parasite infections influence tuberculosis immunopathology and favor rapid sputum conversion of pulmonary tuberculosis patients.Annals of clinical microbiology and antimicrobials · 2024Article
- Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives.International journal of molecular sciences · 2024Review
- Severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-α.Scientific reports · 2024Article
- Article
- Two new and effective food-extracted immunomodulatory agents exhibit anti-inflammatory response activity in the hACE2 acute lung injury murine model of COVID-19.Frontiers in immunology · 2024Article
- The glycosaminoglycan-binding chemokine fragment CXCL9(74-103) reduces inflammation and tissue damage in mouse models of coronavirus infection.Frontiers in immunology · 2024Article
- Protein Interaction Analysis and Molecular Simulation of the Anti-Inflammatory Activities inInternational journal of inflammation · 2024Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
Abstract
Coronaviruses were first discovered in the 1960s and are named due to their crown-like shape. Sometimes, but not often, a coronavirus can infect both animals and humans. An acute respiratory disease, caused by a novel coronavirus (severe acute respiratory syndrome coronavirus-2 or SARS-CoV-2 previously known as 2019-nCoV) was identified as the cause of coronavirus disease 2019 (COVID-19) as it spread throughout China and subsequently across the globe. As of 14th July 2020, a total of 13.1 million confirmed cases globally and 572,426 deaths had been reported by the World Health Organization (WHO). SARS-CoV-2 belongs to the β-coronavirus family and shares extensive genomic identity with bat coronavirus suggesting that bats are the natural host. SARS-CoV-2 uses the same receptor, angiotensin-converting enzyme 2 (ACE2), as that for SARS-CoV, the coronavirus associated with the SARS outbreak in 2003. It mainly spreads through the respiratory tract with lymphopenia and cytokine storms occuring in the blood of subjects with severe disease. This suggests the existence of immunological dysregulation as an accompanying event during severe illness caused by this virus. The early recognition of this immunological phenotype could assist prompt recognition of patients who will progress to severe disease. Here we review the data of the immune response during COVID-19 infection. The current review summarizes our understanding of how immune dysregulation and altered cytokine networks contribute to the pathophysiology of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.